Cytokinetics analyst coverage
WebAnalyst Estimates Options Snapshot Stock Price Targets Yearly Numbers Estimates CYTK will report 2024 earnings on 02/23/2024 EPS Estimate 2024 2024 2024 2024 -10 -5 0 … WebApr 5, 2024 · According to analysts' consensus price target of $56.21, Cytokinetics has a forecasted upside of 60.7% from its current price of $34.99. Amount of Analyst …
Cytokinetics analyst coverage
Did you know?
WebOct 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. WebJul 19, 2024 · The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) ( United States and Canada ) or (706) 679-3078 (international) and typing in the passcode 2984784.
WebFeb 27, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK - Get Rating) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports.One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy … WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth …
WebCytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. Stock Information Press Releases WebOur Corporate Responsibility Framework. Keep Patients at the Center of our Work. Continue to embed patient centricity across all stages of our business. Maintain strong …
WebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ...
WebFor more in-depth coverage of Tesla Motors, ... Analyst Price Forecast Suggests 12.52% Upside. As of April 6, 2024, the average one-year price target for Tesla Motors is $203.14. The forecasts ... porth meaningWebApr 10, 2024 · Trevor Immelman faced the tall task of being named CBS Sports’ lead golf analyst in January, replacing Nick Faldo in the 18th tower, but he soared into this weekend’s coverage of the Masters. porth mear coveWebMar 7, 2024 · Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Mizuho Posted by Defense World Staff on Mar 7th, 2024 Mizuho assumed coverage on shares of Cytokinetics ( NASDAQ:CYTK – Get... porth menshedWebMar 3, 2024 · Following the latest upgrade, the current consensus, from the 13 analysts covering Cytokinetics, is for revenues of US$54m in 2024, which would reflect a stressful 43% reduction in... porth mawgan cornwallWeb2 days ago · CYTOKINETICS, INC. : Trading strategies, financial analysis, commentaries and investment guidance for CYTOKINETICS, INC. Stock Nasdaq: Nasdaq porth meaning cornwallWebCYTK Stock 12 Months Forecast. $58.50. (66.24% Upside) Based on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19. porth mellin coatWeb17 rows · Mar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference … porth medical centre